Celltrion

068270.KO

120.70 USD

-2.99

-2.42%

Overview

Last close

120.70 usd

Market cap

26.28B usd

52 week high

167.56 usd

52 week low

104.26 usd

Target price

161.05 usd

Valuation

P/E

N/A

Forward P/E

38.1679

Price/Sales

10.8385

Price/Book Value

2.2109

Enterprise Value

26.94B usd

EV/Revenue

11.1335

EV/EBITDA

37.0164

Key financials

Revenue TTM

2.42B usd

Gross Profit TTM

1.14B usd

EBITDA TTM

619.28M usd

Earnings per Share

N/A usd

Dividend

0.49 usd

Total assets

14.28B usd

Net debt

790.71M usd

About

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.